UnfoldIP

Company patents

Flamel Ireland Limited

Flamel Ireland Limited's patent strategy is overwhelmingly concentrated in Pharmaceutical Preparations, accounting for 93.2% of its portfolio, which saw a significant surge in 2024 with 32 patents (YoY +255.6%) before a notable decline in 2025 (-31.2%) and so far in 2026 (-72.7%), suggesting a potential shift from its previous rapid expansion in this core area. Despite this, the company maintains a smaller, but steadily growing, focus on Therapeutic Activity (Pharma), which experienced 100.0% YoY growth in 2025.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

74 US filings (since 2023) · 2 categories · 1 themes

Targeted Drug Formulation Delivery

Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.

Pharmaceutical Preparations
Who else files here? →
61since 2023
-41.4%YoY

Patents

Showing 1-10 of 90

Page 1 of 9
US 20260144768 A1APPLICATION
A61K31/191

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Filed:2025-12-05Pub:2026-05-28
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 20260112471 A1APPLICATION
G16H20/10

STREAMLINING FULFILLMENT OF PRESCRIPTIONS SUBJECT TO ELEVATED REGULATION

Filed:2025-10-17Pub:2026-04-23
Applicant:Flamel Ireland Limited

A fulfillment system includes a platform for facilitating fulfillment of a prescription for a regulated product, such as a prescription drug, which also has a REMS, along with any applicable controlled substance scheduling requirements. The platform communicates with a computer network of a healthcare provider's office where a healthcare provider or other authorized prescriber issues a prescription for a patient. The platform also communicates with a pharmacy, such as a specialty pharmacy, for fulfillment of the prescription. The system electronically populates documents satisfying documentation requirements pertaining to a REMS, controlled substances regulations, prescriptions, other pertinent patient information, and/or other regulations or rules thereby eliminating paper and redundant documents and reducing the burden on the healthcare provider/healthcare system.

US D1122750 S1APPLICATION

Nightly dose packet storage set

Filed:2024-04-26Pub:2026-04-21
Applicant:Flamel Ireland Limited
US 20260097010 A1APPLICATION
A61K31/22

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Filed:2025-12-12Pub:2026-04-09
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 20260091013 A1APPLICATION
A61K31/22

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Filed:2025-10-07Pub:2026-04-02
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 20260083696 A1APPLICATION
A61K31/22

MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Filed:2025-10-01Pub:2026-03-26
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 12551457 B1GRANTED
A61K31/191

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Filed:2023-05-01Pub:2026-02-17
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 20260014111 A1APPLICATION
A61K31/22

MODIFIED RELEASE GAMMA- HYDROXYBUTYRATE FORMULATIONS HAVING IMPROVED PHARMACOKINETICS

Filed:2025-09-22Pub:2026-01-15
Applicant:Flamel Ireland Limited

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

US 20250387361 A1APPLICATION
A61K31/19

METHODS OF ADMINISTERING GAMMA-HYDROXYBUTYRATE COMPOSITIONS WITH DIVALPROEX SODIUM

Filed:2025-08-22Pub:2025-12-25
Applicant:Flamel Ireland Limited

Oral pharmaceutical compositions of gamma-hydroxybutyrate (GHB) suitable for concomitant administration with a dose of divalproex sodium (DVP) without materially altering the dosage amount of either drug are provided. Also provided are therapeutic uses of the compositions for the treatment of one or more symptoms of narcolepsy.

US D1102889 S1APPLICATION

Nightly dose packet storage set

Filed:2024-04-26Pub:2025-11-25
Applicant:Flamel Ireland Limited
12345…9